Who wrote the check and why it matters
Isomorphic Labs, the London-based AI drug discovery unit founded in 2021 to extend Google DeepMind's AlphaFold breakthroughs, has secured $5 billion in fresh capital. Sequoia Capital and Greenoaks are co-leading the Series C that the company plans to unveil Tuesday, joined by new investor Andreessen Horowitz and returning investors Thrive Capital, GV and CapitalG. The company did not share a valuation, though Bloomberg previously said the round targeted $5 billion at about a $50 billion valuation.
The war chest follows a May raise of $2.1 billion. Isomorphic is running its own target discovery work in cancer, immune conditions and inflammation, while also partnering with Eli Lilly, Novartis and Johnson & Johnson.
What the money builds
The plan, according to CEO Demis Hassabis: push faster toward human testing and scale a platform designed to generate a very large pipeline. "What we're trying to build is a platform to do hundreds of drugs a year," he said, adding the focus is on technologies and infrastructure that enable that at scale rather than any single program. The company says it has more than 20 programs in motion and is approaching preclinical work on its first oncology effort.
Earlier this year, Hassabis said the first clinical trial might start before 2026 draws to a close. In a November interview, he declined to give a new timeline for the initial cancer target, but said regulatory filings are progressing and that there will be more news in 2027.
Another goal for this raise is breadth. Isomorphic has emphasized small molecule drugs to date, and Hassabis said the company now wants to pursue "pretty much all modalities," moving into macromolecules (biologics) and other medicine types to reach more targets.
Savvy investors often look to new tools to gain a subtle advantage. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.
The AI drug race and the edge backers see
No medicine designed by AI has yet been cleared by regulators. The field is getting more crowded, though, with newcomers like Chai Discovery and listed players such as Insilico Medicine, which is running a late-stage clinical trial in China of an AI-discovered therapy.
According to Konstantine Buhler, a partner at Sequoia, his firm's confidence stems from how Isomorphic builds its models. He pointed to identified scaling laws - patterns that guide how models improve with added compute and data - as the reason Sequoia believes the company can hit clinical testing. "That's huge, because you at least know where you're going. You're not just throwing capital and resources blindly - you're highly informed," Buhler said.
Alphabet ties, compute supply and the investor takeaway
This is Isomorphic's first fundraise since Alphabet's August shuffle, which shifted Hassabis from Google DeepMind CEO to chair of that division and Alphabet's chief scientist. After more than 15 years running DeepMind and nearly three years overseeing Google's combined AI work, he said the new roles let him focus on guiding the science. Waymo, Alphabet's self-driving unit, is another example of an in-house project that has tapped outside capital and debt to grow.
Compute access remains a swing factor for AI startups. Following Nvidia CEO Jensen Huang's resignation last week, some companies have fretted about chip supply. Hassabis said Isomorphic has "very secure compute pipelines," noting the "advantage" of being close to Google's cloud and other resources.
Google also designs its own chips that compete with Nvidia's offerings. "We've got a lot of ways we can deal with whatever comes," he said.
The bottom line: heavyweight investors are backing scale in AI-first drug discovery. Watch for whether Isomorphic converts its expanded modality reach, 20-plus programs and oncology preclinical milestone into regulatory filings on the 2026 to 2027 timetable - a set of catalysts that could reset how markets price AI-led biotech.
Learning how artificial intelligence can inform decisions can sharpen long term results. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.
